Page 92 - NobleCon20-Book-Project

Health Care
Date November 19, 2024 Health Care
52wk High $1.73
52wk Low $0.58 Hoth Therapeutics, Inc. HOTH $0.81
590 Madison Avenue
New York, NY 10022

(USD - in millions) hoththerapeutics.com
Market Cap 5.6
Enterprise (2.3)
Basic Shares Out. 6.90 COMPANY OVERVIEW
Float 6.84
Institutional Holdings 4.84% Detailed Analysis:Channelchek.com
Short Interest 0.62
Avg. 90-Day Volume 3.55 Hoth Therapeutics is a clinical-stage biopharmaceutical company
dedicated to developing innovative, impactful, and ground-breaking
treatments with a goal to improve patient quality of life. We are a
catalyst in early-stage pharmaceutical research and development,
EPS Data elevating drugs from the bench to pre-clinical and clinical testing.
Utilizing a patient-centric approach, we collaborate and partner with a
2022 2023 2024 team of scientists, clinicians, and key opinion leaders to seek out and
CQ1 (2.75) (0.88) (0.46) investigate therapeutics that hold immense potential to create
CQ2 (2.25) (0.57) (0.24) breakthroughs and diversify treatment options.

CQ3 (2.05) (0.60) (0.31)
CQ4 (2.72) (0.31) (0.35)
CY (9.50) (2.30) (1.36) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.09
ROE (ttm) -83.41
Debt-to-Total Cap. (mrq) 0.45
Fiscal Year End 31-Dec
590 Madison ANew York NY 10022

Key Executives
CEO: Knie, Robb
CFO: Briones, David
COO: Springer, Hayley
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures